Guardion Health Sciences CCO Craig Sheehan departs; receives $148k separation plus $35k bonus

Guardion Health Sciences, Inc.

Craig Sheehan terminated as Chief Commercial Officer effective July 10, 2024.
Separation payment of approximately $148,000 plus a $35,000 retention bonus.
Sheehan managed the Viactiv brand, which was sold to Doctor's Best on May 31, 2024.
Resigned all officer/director positions including at subsidiaries.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Craig Sheehan

Chief Commercial Officer

Guardion Health Sciences, Inc.

Effective: 2024-07-10
Filed: July 15, 2024, 7:59 PM ET

On July 10, 2024 (the “Separation Date”), Guardion Health Sciences, Inc. (the “Company”) entered into a Separation Agreement and General Release (the “Separation Agreement”) with Craig Sheehan, its Chief Commercial Officer, whereby the Company and Mr. Sheehan mutually agreed to terminate Mr. Sheehan’s employment with the Company as of the Separation Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig Sheehan was terminated as Chief Commercial Officer at Guardion Health Sciences, Inc..

Action: terminated
Role: Chief Commercial Officer

Exact text from the filing

On July 10, 2024 (the “Separation Date”), Guardion Health Sciences, Inc. (the “Company”) entered into a Separation Agreement and General Release (the “Separation Agreement”) with Craig Sheehan, its Chief Commercial Officer, whereby the Company and Mr. Sheehan mutually agreed to terminate Mr. Sheehan’s employment with the Company as of the Separation Date.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-027827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.